B. Riley Lowers Vincerx Pharma (NASDAQ:VINC) Price Target to $6.00

Vincerx Pharma (NASDAQ:VINC – Get Rating) had its target price dropped by research analysts at B. Riley from $12.00 to $6.00 in a research note issued on Tuesday, The Fly reports. B. Riley’s price objective would suggest a potential upside of 227.87% from the company’s previous close.

A number of other research analysts have also recently weighed in on VINC. Chardan Capital dropped their price objective on shares of Vincerx Pharma from $11.00 to $4.00 in a report on Tuesday. SVB Leerink lowered their price target on shares of Vincerx Pharma from $19.00 to $6.00 and set an “outperform” rating for the company in a report on Tuesday. Zacks Investment Research downgraded shares of Vincerx Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, April 28th. Finally, HC Wainwright upped their price target on shares of Vincerx Pharma from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, March 29th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Vincerx Pharma currently has an average rating of “Buy” and an average target price of $14.61.

NASDAQ:VINC opened at $1.83 on Tuesday. The company’s 50-day moving average price is $2.57 and its 200-day moving average price is $5.85. The company has a market cap of $38.54 million, a P/E ratio of -0.70 and a beta of 1.66. Vincerx Pharma has a twelve month low of $1.40 and a twelve month high of $18.43.

Vincerx Pharma (NASDAQ:VINC – Get Rating) last issued its earnings results on Tuesday, March 29th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.08. As a group, analysts expect that Vincerx Pharma will post -3.17 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in VINC. Long Focus Capital Management LLC acquired a new stake in shares of Vincerx Pharma during the 4th quarter valued at about $1,429,000. Hollencrest Capital Management bought a new stake in shares of Vincerx Pharma during the fourth quarter worth $102,000. Hudson Bay Capital Management LP bought a new stake in shares of Vincerx Pharma during the third quarter worth $3,005,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Vincerx Pharma during the fourth quarter valued at $83,000. Finally, Russell Investments Group Ltd. lifted its stake in Vincerx Pharma by 12.3% in the fourth quarter. Russell Investments Group Ltd. now owns 63,450 shares of the company’s stock valued at $644,000 after buying an additional 6,934 shares during the period. 78.01% of the stock is currently owned by institutional investors.

About Vincerx Pharma (Get Rating)

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies.

Featured Stories